AR053306A1 - Derivados de pirazolopiridina. procesos de obtencion y composiciones farmaceuticas. - Google Patents
Derivados de pirazolopiridina. procesos de obtencion y composiciones farmaceuticas.Info
- Publication number
- AR053306A1 AR053306A1 ARP050102779A ARP050102779A AR053306A1 AR 053306 A1 AR053306 A1 AR 053306A1 AR P050102779 A ARP050102779 A AR P050102779A AR P050102779 A ARP050102779 A AR P050102779A AR 053306 A1 AR053306 A1 AR 053306A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- lower alkyl
- cycloalkyl
- aryl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- -1 hydroxyimino, carbamoyloxy Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
Abstract
Procesos de obtencion y composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) en el cual R1 es (1) alquilo inferior sustituido opcionalmente por halogeno, cicloalquilo (inferior), alcoxi inferior, hidroxi, hidroxi protegido, cicloalquiloxi (inferior), ariloxi, hidroxiimino, carbamoiloxi sustituido opcionalmente por alquilo inferior, heterociclilo sustituido o no sustituido (donde dicho alcoxi inferior está sustituido opcionalmente por cicloalquilo (inferior), arilo sustituido o no sustituido heteroarilo sustituido o no sustituido), (2) alquenilo inferior sustituido opcionalmente por ciano o carbamoílo sustituido opcionalmente por arilo que puede poseer halogeno, (3) cicloalquilo (inferior), (4) acilo, (5) cian, (6) arilo sustituido no sustituido, o (7) heteroarilo sustituido o no sustituido; R2 es R5 o -(A1)p-X-A2-R5, donde p es 0 o 1 A1 es alquileno C1-2 o -CH=CH- A2 es un grupo heterocíclico divalente, o (CH2)n- o -(CH=CH)m- [donde n es un entero que puede oscilar de 1 a 6 y m es un entero que puede oscilar de 1 a 3]; X es un enlace simple, -CH2- u -O-, y R5 es hidroxi, hidroxi protegido, ciano, acilo, carboxi, carboxi protegido, hidroxiimino-alquilo (inferior), o-CONR6R7 [donde R6 es H o alquilo inferior, y R7 es H o -(C2)q-Y-R8 (donde q es 0, 1, 2 o 3, Y es un enlace, -O-, o -CH(R9)-CH2-(donde R9 es alquilo inferior, carboxi o carboxi protegido), y R8 es (1) alquilo, inferior, (2) arilo sustituido o no sustituido, (3) heteroarilo sustituido o no sustituido, (4) heterociclilo sustituido o no sustituido, o (5) cicloalquilo (inferior) sustituido o no sustituido), o de manera alternativa R6 y R7, junto con el átomo de N al que se encuentran nidos, representan un grupo azaheterociclilo sustituido o no sustituido]; R3 es (1) arilo sustituido o no sustituido, (2) heteroarilo sustituido o no sustituido, (3) heterociclilo sustituido o no sustituido, (4) cicloalquilo (inferior), o (5) alquilo inferior sustituido opcionalmente por (a) cicloalquilo (inferior), (b) heterociclilo sustituido o no sustituido, (c) arilo sustituido o no sustituido, o (d) heteroarilo sustituido o no sustituido; y R4 es alquilo inferior; o una sal aceptable para uso farmacéutico de los mismos, o profármaco de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004903691A AU2004903691A0 (en) | 2004-07-05 | Pyrazolopyridine Derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053306A1 true AR053306A1 (es) | 2007-05-02 |
Family
ID=35431022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102779A AR053306A1 (es) | 2004-07-05 | 2005-07-04 | Derivados de pirazolopiridina. procesos de obtencion y composiciones farmaceuticas. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7459451B2 (es) |
| EP (1) | EP1763528B1 (es) |
| JP (1) | JP5092402B2 (es) |
| KR (1) | KR20070042164A (es) |
| CN (1) | CN1980927A (es) |
| AR (1) | AR053306A1 (es) |
| AT (1) | ATE415400T1 (es) |
| CA (1) | CA2571588A1 (es) |
| DE (1) | DE602005011286D1 (es) |
| ES (1) | ES2319797T3 (es) |
| MX (1) | MXPA06014699A (es) |
| TW (1) | TW200606162A (es) |
| WO (1) | WO2006004188A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080065704A (ko) | 2005-11-09 | 2008-07-14 | 콤비네이토릭스, 인코포레이티드 | 의학적 이상의 치료 방법들, 조성물들, 및 키트들 |
| EP2038279A2 (en) | 2006-06-06 | 2009-03-25 | Avigen, Inc. | Substituted pyrazolo [1,5- alpha] pyridine compounds and their methods of use |
| NZ579645A (en) | 2007-03-14 | 2012-01-12 | Ranbaxy Lab Ltd | Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors |
| US7536799B2 (en) * | 2007-06-07 | 2009-05-26 | Keson Industries | Chalk line apparatus with strategically located chalk fill opening |
| WO2009062308A1 (en) * | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| EP2070929A1 (en) | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| WO2009109525A1 (en) * | 2008-03-03 | 2009-09-11 | Nycomed Gmbh | Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease |
| US20110105510A1 (en) * | 2008-06-17 | 2011-05-05 | Hiroshi Ishikawa | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| WO2010016846A1 (en) * | 2008-08-08 | 2010-02-11 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| FR2951172B1 (fr) * | 2009-10-13 | 2014-09-26 | Pf Medicament | Derives pyrazolopyridines en tant qu'agent anticancereux |
| KR101774035B1 (ko) * | 2009-10-30 | 2017-09-01 | 얀센 파마슈티카 엔.브이. | 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도 |
| WO2011142724A1 (en) * | 2010-05-14 | 2011-11-17 | Agency For Science, Technology And Research | Novel antimicrobial compounds and uses thereof |
| EP2593453B1 (en) | 2010-07-15 | 2014-09-17 | Bristol-Myers Squibb Company | Azaindazole compounds |
| WO2012019954A1 (en) | 2010-08-12 | 2012-02-16 | Evotec (Uk) Ltd. | Pyrazolopyridine compounds as pde10a inhibitors |
| US9266880B2 (en) | 2010-11-12 | 2016-02-23 | Bristol-Myers Squibb Company | Substituted azaindazole compounds |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| ES2659763T3 (es) | 2011-02-14 | 2018-03-19 | The Regents Of The University Of Michigan | Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados |
| EP2760870B1 (en) | 2011-09-27 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| EP2991647B1 (en) | 2013-05-02 | 2019-04-24 | The Regents Of The University Of Michigan | Deuterated amlexanox with improved metabolic stability |
| WO2015153959A2 (en) * | 2014-04-04 | 2015-10-08 | The Regents Of The University Of Michigan | Small molecule inhibitors of mcl-1 and uses thereof |
| CN104230811B (zh) * | 2014-07-30 | 2016-09-28 | 斯芬克司药物研发（天津）股份有限公司 | 一种吡唑吡啶化合物及其制备方法 |
| PE20181348A1 (es) * | 2015-10-09 | 2018-08-22 | Abbvie Sarl | PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y METODO DE USO |
| EP3407974A4 (en) | 2016-01-29 | 2019-08-28 | The Regents Of The University Of Michigan | Amlexanox Analogs |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JOP20190126A1 (ar) * | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| CN110475817A (zh) * | 2017-03-28 | 2019-11-19 | 嘉吉公司 | 易水混溶性β-葡聚糖悬浮液 |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| PT3723807T (pt) | 2017-12-14 | 2021-11-26 | H Lundbeck As | Tratamentos de associação que compreendem a administração de 1h-pirazolo[4,3-b]piridinas |
| CN117447475A (zh) | 2017-12-20 | 2024-01-26 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
| CN108558876B (zh) * | 2018-05-28 | 2020-08-04 | 中南大学 | 吡唑[3,4-b]并吡啶类衍生物及其制备方法和应用 |
| US12486269B2 (en) | 2024-02-08 | 2025-12-02 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| WO2025171341A2 (en) * | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4822799A (en) * | 1988-01-27 | 1989-04-18 | Sandoz Pharm. Corp. | Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals |
| US5024999A (en) * | 1988-04-26 | 1991-06-18 | Nissan Chemical Industries Ltd. | Pyrazolopyridine type mevalonolactones useful as pharmaeuticals |
| JP3130342B2 (ja) * | 1991-10-04 | 2001-01-31 | 日産化学工業株式会社 | 動脈硬化性血管内膜肥厚抑制薬 |
| US6326379B1 (en) * | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| JP2002020386A (ja) * | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
| JP2004526789A (ja) * | 2001-04-25 | 2004-09-02 | アルタナ ファルマ アクチエンゲゼルシャフト | 新規フタラジノン |
| WO2004024728A2 (en) * | 2002-09-16 | 2004-03-25 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
| MXPA05007462A (es) | 2003-01-09 | 2006-01-27 | Astellas Pharma Inc | Derivados de pirrolopiridazina. |
-
2005
- 2005-07-01 WO PCT/JP2005/012618 patent/WO2006004188A1/en not_active Ceased
- 2005-07-01 MX MXPA06014699A patent/MXPA06014699A/es active IP Right Grant
- 2005-07-01 CN CNA2005800225451A patent/CN1980927A/zh active Pending
- 2005-07-01 US US11/171,320 patent/US7459451B2/en not_active Expired - Fee Related
- 2005-07-01 AT AT05757839T patent/ATE415400T1/de not_active IP Right Cessation
- 2005-07-01 ES ES05757839T patent/ES2319797T3/es not_active Expired - Lifetime
- 2005-07-01 CA CA002571588A patent/CA2571588A1/en not_active Abandoned
- 2005-07-01 DE DE602005011286T patent/DE602005011286D1/de not_active Expired - Lifetime
- 2005-07-01 JP JP2006553787A patent/JP5092402B2/ja not_active Expired - Fee Related
- 2005-07-01 EP EP05757839A patent/EP1763528B1/en not_active Expired - Lifetime
- 2005-07-01 KR KR1020077002746A patent/KR20070042164A/ko not_active Withdrawn
- 2005-07-04 TW TW094122527A patent/TW200606162A/zh unknown
- 2005-07-04 AR ARP050102779A patent/AR053306A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1980927A (zh) | 2007-06-13 |
| JP2008505056A (ja) | 2008-02-21 |
| US20060004003A1 (en) | 2006-01-05 |
| EP1763528A1 (en) | 2007-03-21 |
| EP1763528B1 (en) | 2008-11-26 |
| US7459451B2 (en) | 2008-12-02 |
| MXPA06014699A (es) | 2007-03-26 |
| DE602005011286D1 (en) | 2009-01-08 |
| CA2571588A1 (en) | 2006-01-12 |
| KR20070042164A (ko) | 2007-04-20 |
| ES2319797T3 (es) | 2009-05-12 |
| JP5092402B2 (ja) | 2012-12-05 |
| WO2006004188A1 (en) | 2006-01-12 |
| ATE415400T1 (de) | 2008-12-15 |
| TW200606162A (en) | 2006-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053306A1 (es) | Derivados de pirazolopiridina. procesos de obtencion y composiciones farmaceuticas. | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| RU2448976C2 (ru) | Ингибиторы hcv/вич и их применение | |
| AR042833A1 (es) | Derivados de pirrolopiridazina y procedimiento para su preparacion | |
| RU2006109004A (ru) | 7-аминоалкилиденилгетероциклические хинолоны и нафтиридоны | |
| AR028952A1 (es) | Antagonistas receptores de trombina | |
| AR105340A2 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden | |
| PE20090042A1 (es) | Analogos de ciclopamina | |
| EP1325921A3 (en) | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | |
| AR079634A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
| EA200970478A1 (ru) | Аналоги тиофена для лечения или предупреждения флавивирусных инфекций | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR051093A1 (es) | Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa | |
| AR048413A1 (es) | Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
| AR064319A1 (es) | Compuestos y composiciones farmaceuticas derivadas de sulfonamida ciclicos, proceso de preparacion y usos en el tratamiento de trastornos vasomotrices, sexuales, gastrointestinales y otros | |
| AR062606A1 (es) | Compuestos de isoindolina 5-sustituidos | |
| AR057023A1 (es) | Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa | |
| AR055053A1 (es) | Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas. | |
| AR057209A1 (es) | Compuestos para el tratamiento de trastornos inflamatorios y enfermedades microbianas | |
| UA98966C2 (ru) | Производные бензазепина, пригодные для использования в качестве антагонистов вазопрессина | |
| UY26048A1 (es) | Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica | |
| EA201070804A1 (ru) | (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения | |
| WO2009010789A3 (en) | Pyrimidine derivatives 934 | |
| AR059136A1 (es) | Derivados de indol-3-il-carbonil-espiro-piperidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |